TW201713685A - Truncated von Willebrand factor polypeptides for treating hemophilia - Google Patents
Truncated von Willebrand factor polypeptides for treating hemophiliaInfo
- Publication number
- TW201713685A TW201713685A TW105116001A TW105116001A TW201713685A TW 201713685 A TW201713685 A TW 201713685A TW 105116001 A TW105116001 A TW 105116001A TW 105116001 A TW105116001 A TW 105116001A TW 201713685 A TW201713685 A TW 201713685A
- Authority
- TW
- Taiwan
- Prior art keywords
- von willebrand
- willebrand factor
- treating hemophilia
- truncated von
- factor polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15168930 | 2015-05-22 | ||
| EP16163239 | 2016-03-31 | ||
| PCT/EP2016/061443 WO2016188907A1 (en) | 2015-05-22 | 2016-05-20 | Truncated von willebrand factor polypeptides for treating hemophilia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201713685A true TW201713685A (en) | 2017-04-16 |
Family
ID=56024318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105116001A TW201713685A (en) | 2015-05-22 | 2016-05-23 | Truncated von Willebrand factor polypeptides for treating hemophilia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10688157B2 (ko) |
| EP (1) | EP3297656B1 (ko) |
| JP (1) | JP6573989B2 (ko) |
| KR (1) | KR20180006453A (ko) |
| CN (1) | CN107787328B (ko) |
| AU (1) | AU2016266627A1 (ko) |
| BR (1) | BR112017023785A2 (ko) |
| CA (1) | CA2986626A1 (ko) |
| DK (1) | DK3297656T3 (ko) |
| ES (1) | ES2774011T3 (ko) |
| HK (1) | HK1250625A1 (ko) |
| IL (1) | IL255652A (ko) |
| MX (1) | MX2017014503A (ko) |
| RU (1) | RU2017145014A (ko) |
| SG (2) | SG10201910896UA (ko) |
| TW (1) | TW201713685A (ko) |
| WO (1) | WO2016188907A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3538133T3 (da) * | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| JP2020530436A (ja) | 2017-06-22 | 2020-10-22 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | トランケート型ｖｗｆによるｆｖｉｉｉの免疫原性の調節 |
| AU2018390797A1 (en) | 2017-12-19 | 2020-07-02 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| JP2021523878A (ja) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病ａを処置する方法 |
| CN113105562B (zh) * | 2018-09-26 | 2023-12-01 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii在制备融合蛋白中的应用 |
| KR20220029733A (ko) * | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| WO1997040145A1 (en) | 1996-04-24 | 1997-10-30 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| PT1079805E (pt) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| JP2005518181A (ja) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
| ES2331909T3 (es) | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| WO2003093313A2 (en) | 2002-04-29 | 2003-11-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CN1767857A (zh) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | 聚合物－因子ⅷ部分共轭物 |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| EP2298347B1 (en) | 2003-05-06 | 2015-09-30 | Biogen Hemophilia Inc. | Clotting factor chimeric proteins for treatment of a hemostatic disorder |
| CN1802386B (zh) | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
| DK1699821T3 (da) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| WO2006053299A2 (en) | 2004-11-12 | 2006-05-18 | Bayer Healthcare Llc | Site-directed modification of fviii |
| ES2434035T3 (es) | 2004-12-27 | 2013-12-13 | Baxter International Inc. | Conjugados de polímero-factor von Willebrand |
| DE102005002444A1 (de) | 2005-01-19 | 2006-07-27 | Wella Ag | Behälter mit einem Ventil |
| CA2604299A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| CA2647314A1 (en) | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| PL3896090T3 (pl) | 2006-06-14 | 2022-05-02 | Csl Behring Gmbh | Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| DK2167117T3 (da) * | 2007-06-13 | 2012-11-19 | Csl Behring Gmbh | Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser |
| KR101648734B1 (ko) | 2008-06-24 | 2016-08-18 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| JP5876416B2 (ja) | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用 |
| US9758292B2 (en) * | 2011-06-17 | 2017-09-12 | Berry Plastics Corporation | Insulated container |
| WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| BR112014017165B1 (pt) | 2012-01-12 | 2023-05-02 | Bioverativ Therapeutics Inc | Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos |
| EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| EP2841451A1 (en) * | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| EP2662083A1 (en) * | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
| CN110054699A (zh) * | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| CN105452289A (zh) | 2013-06-12 | 2016-03-30 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
| CN106456718A (zh) | 2014-01-10 | 2017-02-22 | 比奥根Ma公司 | 因子viii嵌合蛋白及其用途 |
-
2016
- 2016-05-20 JP JP2017560682A patent/JP6573989B2/ja not_active Expired - Fee Related
- 2016-05-20 KR KR1020177037156A patent/KR20180006453A/ko unknown
- 2016-05-20 SG SG10201910896UA patent/SG10201910896UA/en unknown
- 2016-05-20 EP EP16723776.7A patent/EP3297656B1/en active Active
- 2016-05-20 CN CN201680029650.6A patent/CN107787328B/zh active Active
- 2016-05-20 CA CA2986626A patent/CA2986626A1/en not_active Abandoned
- 2016-05-20 US US15/576,055 patent/US10688157B2/en active Active
- 2016-05-20 WO PCT/EP2016/061443 patent/WO2016188907A1/en active Application Filing
- 2016-05-20 RU RU2017145014A patent/RU2017145014A/ru not_active Application Discontinuation
- 2016-05-20 MX MX2017014503A patent/MX2017014503A/es unknown
- 2016-05-20 SG SG11201708755WA patent/SG11201708755WA/en unknown
- 2016-05-20 DK DK16723776.7T patent/DK3297656T3/da active
- 2016-05-20 AU AU2016266627A patent/AU2016266627A1/en not_active Abandoned
- 2016-05-20 ES ES16723776T patent/ES2774011T3/es active Active
- 2016-05-20 BR BR112017023785-7A patent/BR112017023785A2/pt not_active Application Discontinuation
- 2016-05-23 TW TW105116001A patent/TW201713685A/zh unknown
-
2017
- 2017-11-14 IL IL255652A patent/IL255652A/en unknown
-
2018
- 2018-08-02 HK HK18109996.5A patent/HK1250625A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107787328B (zh) | 2021-08-06 |
| US10688157B2 (en) | 2020-06-23 |
| AU2016266627A1 (en) | 2018-01-18 |
| CA2986626A1 (en) | 2016-12-01 |
| BR112017023785A2 (pt) | 2018-07-17 |
| CN107787328A (zh) | 2018-03-09 |
| JP6573989B2 (ja) | 2019-09-11 |
| US20180161402A1 (en) | 2018-06-14 |
| SG10201910896UA (en) | 2020-01-30 |
| EP3297656B1 (en) | 2020-01-08 |
| SG11201708755WA (en) | 2017-12-28 |
| WO2016188907A1 (en) | 2016-12-01 |
| EP3297656A1 (en) | 2018-03-28 |
| ES2774011T3 (es) | 2020-07-16 |
| MX2017014503A (es) | 2018-08-01 |
| JP2018517691A (ja) | 2018-07-05 |
| KR20180006453A (ko) | 2018-01-17 |
| RU2017145014A (ru) | 2019-06-24 |
| HK1250625A1 (zh) | 2019-01-11 |
| IL255652A (en) | 2018-01-31 |
| DK3297656T3 (da) | 2020-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201713685A (en) | Truncated von Willebrand factor polypeptides for treating hemophilia | |
| MX2017011847A (es) | Modulación de inmunidad tumoral por liberación de o2 mediada por proteína. | |
| EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| PH12015500039A1 (en) | Factor viii complex with xten and von willebrand factor protein, and uses thereof | |
| EA201591439A1 (ru) | Препараты полипептида фактора viii | |
| EA201491388A1 (ru) | Рекомбинантные белки фактора viii | |
| BR112016025437A2 (pt) | combinação de lenalidomida e construto de polipeptídeo, e usos destes | |
| MX2016016337A (es) | Polipeptidos apelina. | |
| CY1123011T1 (el) | Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων | |
| WO2014198699A3 (en) | Compounds suitable for treatment of haemophilia | |
| MX2020012397A (es) | Metodos de tratamiento de la hemofilia a. | |
| EA201891138A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| EA201990868A1 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ АКТИВАЦИИ СИГНАЛЬНОЙ СИСТЕМЫ Tie2 | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| SG10201912768YA (en) | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder | |
| MX2018006194A (es) | Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas. | |
| MX2017004520A (es) | Composiciones para tratar heridas. | |
| SG10201912360SA (en) | Truncated von willebrand factor polypeptides for treating hemophilia | |
| JOP20210008A1 (ar) | أنواع أبيراز مذابة، وطرق لاستخدامها | |
| MX2016003871A (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. | |
| EA201690826A1 (ru) | Рекомбинантные гликопротеиды и их применения | |
| EA201690732A1 (ru) | Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций |